Showing results (61-70 of 250) with videos related to
Sort By:
Pageof 25
Melanoma Research|July 22, 2024
Exacerbation of Kaposi sarcoma following BRAF/MEK inhibitor therapy in a melanoma patient: a case report and mechanistic insightAntonios Tsimpidakis, Ioannis-Alexios Koumprentziotis, Evanthia Mastoraki, et al.Journal for Immunotherapy of Cancer|October 17, 2020
Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapyDimitrios C Ziogas, Frosso Kostantinou, Evangelos Cholongitas, et al.Therapeutic Advances in Medical Oncology|October 25, 2021
The diagnosis and management of sarcoid-like reactions in patients with melanoma treated with BRAF and MEK inhibitors. A case series and review of the literatureAmalia Anastasopoulou, Panagiotis T Diamantopoulos, Chrysanthi Skalioti, et al.Therapeutic Advances in Medical Oncology|October 22, 2020
Clinical considerations about the coexistence of melanoma and chronic lymphocytic leukemia in the era of targeted therapies, triggered by rare clinical scenarios. A case series and review of the literaturePanagiotis T Diamantopoulos, Dimitrios Ziogas, Nora-Athina Viniou, et al.Current Oncology Reports|May 16, 2025
State-of-the-art in Metastatic Uveal Melanoma Treatment: A 2025 Update : How to treat Metastatic Uveal Melanoma in 2025Dimitrios C Ziogas, Dimitra Foteinou, Charalampos Theocharopoulos, et al.Journal of Cancer Research and Clinical Oncology|May 4, 2012
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trialChristos Markopoulos, Evagelos Tzoracoleftherakis, Dimitrios Koukouras, et al.Cancer|February 1, 2008
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinionAxel Hauschild, Helen Gogas, Ahmad Tarhini, et al.Journal for Immunotherapy of Cancer|November 4, 2020
When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case reportDimitrios C Ziogas, Aikaterini Gkoufa, Evangelos Cholongitas, et al.Anticancer Research|February 11, 2015
Predictive biomarkers to chemotherapy in patients with advanced melanoma receiving the combination of cisplatin--vinblastine--temozolomide (PVT) as first-line treatment: a study of the Hellenic Cooperative Oncology Group (HECOG)Helena Linardou, George Pentheroudakis, Ioannis Varthalitis, et al.The American Journal of the Medical Sciences|December 21, 2022
Melanuria in a patient with BRAF-mutant metastatic melanoma of unknown primary: Insights on the pathophysiology, differential diagnosis, prognosis, and treatmentPanagiotis Diamantopoulos, Georgios Patavoukas, Andriana Garantzioti, et al.Pageof 25